Medicenna to Announce Second Quarter Fiscal 2023 Financial Results and Operational Highlights on Friday, November 4, 2022

Rhea-AI Summary

Medicenna Therapeutics Corp. (NASDAQ: MDNA) announced a conference call on November 4, 2022, at 8:30 AM ET to discuss its second quarter fiscal 2023 financial results and operational highlights. The live webcast will be accessible through their website. Medicenna specializes in immunotherapy, focusing on advanced IL-2, IL-4, and IL-13 Superkines with MDNA11 showing promise in preferentially stimulating cancer-fighting T cells and NK cells. The IL-4 Empowered Superkine, MDNA55, has received Fast-Track and Orphan Drug status from the FDA.

Positive

• MDNA11 shows superior CD122 binding for enhanced cancer treatment.
• MDNA55 has received Fast-Track and Orphan Drug status from the FDA.

Negative

• None.

TORONTO and HOUSTON, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on November 4, 2022 at 8:30 AM ET to report its second quarter fiscal 2023 financial results and operational highlights.

To access the call, please dial 1-877-407-9716 from Canada or the United States or 1-201-493-6779 internationally, followed by the conference ID: 13733195. To access the live webcast, please visit https://viavid.webcasts.com/starthere.jsp?ei=1573316&tp_key=64173fbac0. Following the live webcast, an archived version of the call will be available on Medicenna’s website.

About Medicenna
Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna's long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna’s early-stage BiSKITs™ program (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna's IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.

FAQ

What date will Medicenna report its fiscal 2023 Q2 results?

Medicenna will report its fiscal 2023 Q2 results on November 4, 2022.

How can I access Medicenna's conference call?

You can access the conference call by dialing 1-877-407-9716 from Canada or the US, or 1-201-493-6779 internationally, using conference ID: 13733195.

What is the focus of Medicenna's drug development?

Medicenna focuses on developing advanced immunotherapies, specifically IL-2, IL-4, and IL-13 Superkines.